Retinol acetate clinical trials
Also written QLT091001.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How each study uses retinol acetate is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- QLT091001
- 5
Studies by the year they started
5 studies that test it; most in 2012 (2)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2012 | 2 |
| 2013 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
QLT Inc. (5)
Studies
Open first, then newest update. How each study uses retinol acetate is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Evaluation of the Effects of Oral QLT091001 in Adults With Impaired Dark AdaptationCompletedPhase 2QLT Inc.NCT01999764Written as QLT091001
- Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65)CompletedPhase 1QLT Inc.NCT01543906Written as QLT091001
- Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01)CompletedPhase 1QLT Inc.NCT01521793Written as QLT091001
- Safety/Proof of Concept Study of Oral QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) MutationsCompletedPhase 1QLT Inc.NCT01014052Written as QLT091001
- Safety and Tolerability of Retinoid QLT091001 in Healthy VolunteersCompletedPhase 1QLT Inc.NCT00765427Written as QLT091001
Codes
What other systems call retinol acetate · ClinicalTrials.gg INT002446
- MeSH (NLM) C009166retinol acetateConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 2K3YP54BYUZURETINOL ACETATEConfirmed FDA, Wikidata
- Wikidata Q27254851zuretinol acetateConfirmed FDA, Wikidata
- NCI Thesaurus C152967Zuretinol AcetateOne source FDA
- DrugBank DB12112One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C009166 | retinol acetate | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 2K3YP54BYU | ZURETINOL ACETATE | Confirmed FDA, Wikidata |
| Wikidata | Q27254851 | zuretinol acetate | Confirmed FDA, Wikidata |
| NCI Thesaurus | C152967 | Zuretinol Acetate | One source FDA |
| DrugBank | DB12112 | — | One source Wikidata |
Also registered as vitamin a acetate (UNII 3LE3D9D6OY · RxNorm 35400).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.